JP7105465B2 - キニーネ塩懸濁液を含む抗癌治療のための局所投与用注射剤組成物及び懸濁液注射剤の製造方法 - Google Patents

キニーネ塩懸濁液を含む抗癌治療のための局所投与用注射剤組成物及び懸濁液注射剤の製造方法 Download PDF

Info

Publication number
JP7105465B2
JP7105465B2 JP2017092609A JP2017092609A JP7105465B2 JP 7105465 B2 JP7105465 B2 JP 7105465B2 JP 2017092609 A JP2017092609 A JP 2017092609A JP 2017092609 A JP2017092609 A JP 2017092609A JP 7105465 B2 JP7105465 B2 JP 7105465B2
Authority
JP
Japan
Prior art keywords
suspension
present
injection
composition
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017092609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017226643A5 (enExample
JP2017226643A (ja
Inventor
ヨン ヨ，オ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2017226643A publication Critical patent/JP2017226643A/ja
Publication of JP2017226643A5 publication Critical patent/JP2017226643A5/ja
Application granted granted Critical
Publication of JP7105465B2 publication Critical patent/JP7105465B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017092609A 2016-06-20 2017-05-08 キニーネ塩懸濁液を含む抗癌治療のための局所投与用注射剤組成物及び懸濁液注射剤の製造方法 Active JP7105465B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0076742 2016-06-20
KR1020160076742A KR101698003B1 (ko) 2016-06-20 2016-06-20 퀴닌 염 현탁액을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물

Publications (3)

Publication Number Publication Date
JP2017226643A JP2017226643A (ja) 2017-12-28
JP2017226643A5 JP2017226643A5 (enExample) 2018-04-19
JP7105465B2 true JP7105465B2 (ja) 2022-07-25

Family

ID=57990872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017092609A Active JP7105465B2 (ja) 2016-06-20 2017-05-08 キニーネ塩懸濁液を含む抗癌治療のための局所投与用注射剤組成物及び懸濁液注射剤の製造方法

Country Status (6)

Country Link
US (1) US10441582B2 (enExample)
EP (1) EP3260138B1 (enExample)
JP (1) JP7105465B2 (enExample)
KR (1) KR101698003B1 (enExample)
CN (1) CN107519130A (enExample)
TW (1) TWI650141B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR128240A1 (es) * 2022-04-07 2024-04-10 Kannar Earth Science Ltd Composiciones y procedimientos para mejorar el rendimiento de las semillas
KR20250156636A (ko) 2024-04-25 2025-11-03 (의) 삼성의료재단 종양 혈관 파괴용 약학 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540478A (ja) 2005-05-09 2008-11-20 ビオスフェレ メディカル エス．エー． ミクロスフェア及び非イオン性造影剤を用いた組成物及び方法
JP2012530697A (ja) 2009-06-24 2012-12-06 オヨン ヨ ヒドロキシクロロキンを含む抗癌治療のための局所投与用注射剤の組成物
JP2014522856A (ja) 2011-07-14 2014-09-08 ランバクシー ラボラトリーズ リミテッド アルテロランおよびピペラキンの安定した投与形態物
CN105560241A (zh) 2015-12-11 2016-05-11 北京夸常生物医疗科技有限公司 二盐酸奎宁在治疗肿瘤中的应用、方法以及药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1015872B (zh) * 1987-06-02 1992-03-18 严清财 痔全脱注射液的制造方法
KR100390332B1 (ko) 2000-08-02 2003-07-07 유원민 항말라리아제와 항암제의 병용투여에 의한 항암제 복합 조성물
CN1465348A (zh) * 2002-07-05 2004-01-07 冯威健 复方消融合剂及其在用作制备治疗肿瘤药物上的应用
KR20060034316A (ko) 2004-07-09 2006-04-24 최병찬 치질 치루를 치료하는 경화제 주사약 제조방법
CN101485669A (zh) * 2009-02-13 2009-07-22 秦克骏 一种治疗肿瘤、痔疮的药物及其制造方法
KR101067443B1 (ko) 2009-06-23 2011-09-27 여오영 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물
WO2013063155A2 (en) * 2011-10-24 2013-05-02 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
KR101365252B1 (ko) * 2012-04-04 2014-02-21 주식회사 아미팜 포스파티딜콜린 함유 주사용 조성물 및 이의 제조방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540478A (ja) 2005-05-09 2008-11-20 ビオスフェレ メディカル エス．エー． ミクロスフェア及び非イオン性造影剤を用いた組成物及び方法
JP2012530697A (ja) 2009-06-24 2012-12-06 オヨン ヨ ヒドロキシクロロキンを含む抗癌治療のための局所投与用注射剤の組成物
JP2014522856A (ja) 2011-07-14 2014-09-08 ランバクシー ラボラトリーズ リミテッド アルテロランおよびピペラキンの安定した投与形態物
CN105560241A (zh) 2015-12-11 2016-05-11 北京夸常生物医疗科技有限公司 二盐酸奎宁在治疗肿瘤中的应用、方法以及药物组合物

Also Published As

Publication number Publication date
EP3260138A1 (en) 2017-12-27
EP3260138B1 (en) 2024-05-01
JP2017226643A (ja) 2017-12-28
KR101698003B1 (ko) 2017-01-19
US20170360769A1 (en) 2017-12-21
EP3260138C0 (en) 2024-05-01
US10441582B2 (en) 2019-10-15
CN107519130A (zh) 2017-12-29
TW201800091A (zh) 2018-01-01
TWI650141B (zh) 2019-02-11

Similar Documents

Publication Publication Date Title
ES2243940T3 (es) Liberacion local controlada de un agente quimioterapeutico para el tratamiento de tumores solidos.
ES2258566T3 (es) Combinaciones de farmacos (por ejemplo, clorpromacina y pentamidina) para el tratamiento de trastornos neoplasicos.
KR101578273B1 (ko) 화학요법적 항종양 약물을 함유하는 나노입자
EP1797874B1 (en) Vascular embolus of paclitaxel-sodium alginate microsphere and its preparation
JP5580409B2 (ja) ヒドロキシクロロキンを含む抗癌治療のための局所投与用注射剤の組成物
EP2952184B1 (en) Pharmaceutical formulation for treating pancreatic cancer
Cheikh et al. Lessons learned from the discovery and development of the sesquiterpene lactones in cancer therapy and prevention
JP2021169534A (ja) 化学療法の改善
KR101563069B1 (ko) 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물
EP3439644B1 (en) Isoflavonoid composition with improved pharmacokinetics
WO2015172712A1 (zh) 维生素c与抗肿瘤药物协同作用的注射用药物组合物
JP7105465B2 (ja) キニーネ塩懸濁液を含む抗癌治療のための局所投与用注射剤組成物及び懸濁液注射剤の製造方法
HK1223844A1 (zh) 用於管理癌症和治疗癌症并存病的方法
JP2017226643A5 (enExample)
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
JP2014221752A (ja) ガン幹細胞に対する分化促進薬及び脳腫瘍治療薬
CN107569496A (zh) 包含水杨酸类化合物和醇类液体硬化剂的抗肿瘤药物组合物及其应用
CN102793730B (zh) 银杏达莫的药物组合物及其制备方法
HK40077741A (en) Method for the management of cancer and treatment of cancer comorbidities
TWI602563B (zh) 橙黃醯胺雙肽衍生物用於治療或預防血管新生相關疾病
US20170182114A1 (en) Aurantiamide dipeptide derivatives for treatment or prevention of angiogenesis-related diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200508

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220524

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220607

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220705

R150 Certificate of patent or registration of utility model

Ref document number: 7105465

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250